

**Reference Number:** FOI202223/110  
**From:** Private Individual  
**Date:** 27 June 2022  
**Subject:** Use of anidulafungin, caspofungin and micafungin in last 12 months

**Q1** What is the number of patients in the last 12 months treated with the following product lines:  
a. anidulafungin  
b. caspofungin  
c. micafungin

**A1** a. Three  
b. Twenty  
c. One

**Q2** What is the split of indication over the last 12 months for the following product lines:  
a. anidulafungin  
b. caspofungin  
c. micafungin

**A2** a.  
i. Urinary Tract Infection  
ii. Yeast Bacteraemia  
iii. Gastrointestinal  
b.  
i. E Faecum - One  
ii. Empirical - Eight  
iii. Candida - Seven  
iv. Pulmonary Yeast - One  
v. Pulmonary Aspergilliosis - One  
vi. Abdominal - Two  
c. Empyema

**Q3** For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2) list the average length of treatment time.

**A3** a.  
i. 4-7 days  
ii. 4-7 days  
iii. 5-7 days  
b.  
i. 14 days  
ii. 7 days  
iii. 12 days  
iv. 23 days  
v. 14 days  
vi. 10 days

c. 12 days